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1. Introduction
Glaucoma has long been considered an irreversible progressive optic neuropathy with
associated visual loss. Elevated intraocular pressure (IOP) was once considered the main
modifiable risk for progression of glaucoma and has been the target for treatment. The
pathogenesis of glaucoma was originally based on the mechanical and vascular dysregulation
theory, however, this has evolved over the past decade. With the classification of low tension
glaucoma, it is now recognized that the damage that occurs in the optic disc is not directly due
to the elevated IOP and may be independent of this risk factor. Even though clinicians may
aim for a target pressure, progression of optic disc cupping and visual field loss can still
continue despite normal IOPs.
In contemplating a systematic approach to neuroprotection, the main areas to target include
1) neurotoxic agents such as nitric oxide and glutamate, 2) deprivation of internal neurotrophic
factors 3) balancing self-repair with self-destruction in ocular nerve tissue and, 4) ocular blood
flow and combating ischemia [1,2,3]. Focus in this chapter is dedicated to reviewing the
mechanisms involved in the pathophysiology of neurodegeneration, target processes that offer
neuroprotection, and the chemical and genetic interventions bearing potential for increasing
retinal ganglion cell (RGC) survival. Glaucoma has cellular and molecular neurodegenerative
pathways akin to those of other neurodegenerative disorders such as alzheimer’s and parkin‐
sons, which increases the accessibility to possible treatment options.
Gene therapy targets increased conventional and uveoscleral outflow, reduced aqueous
production and prevention of wound healing in addition to neuroprotection. Interfering with
the apoptosis cycle by gene therapy has also being considered by increasing neurotrophic
factors [4]. Intravitreal injections of brain-derived neurotrophic factor (BDNF), a neurotrophin
that improves neurogenesis and survival are being studied. Interestingly it has recently been
noted in animal models that short periods of hyperglycemia may be protective to the retinal
ganglion cells during periods of elevated intra ocular pressure [5].
© 2013 Mowatt and Intosh; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
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Neuroprotection is the strategy to prevent retinal ganglion cell death. There have been several
methods, many still experimental, aimed at reducing glutamate excitotoxicity, nitric oxide,
free radical production and tumour necrosis factor (TNF) inhibition [1-4,6]. With the latest
research, glaucoma, which was once thought to be an optic neuropathy, then a retinal disease,
is now being considered a neurodegenerative disease, like alzheimer and parkinson [7].
This chapter will review the present pathophysiology theories of neurodegeneration in
glaucoma and highlight the latest updates in neuroprotection strategies, mechanisms that
block apoptosis and improving the survival and functionality of the retinal ganglion cell.
2. Retinal ganglion cell death
The neurodegeneration seen in glaucoma is as an end result of apoptosis (programmed cell
death) of the retinal ganglion cell (RGC). When the retinal ganglion cell dies, there is a
degenerative change along the axon with the resulting clinical findings including thinning of
the retinal nerve fiber layer (objectively measured by Optical Coherence Tomography,
Heidelberg Retinal Tomography or GDx) and increased optic disc cupping. Retinal ganglion
cell apoptosis results in visual field loss and ultimately loss of vision in glaucoma. There are
several etiologies for retinal ganglion cell (RGC) death which occurs with and without elevated
intraocular pressures.
Retinal ganglion cell apoptosis is thought to be a result of several factors:
• increased intraocular pressure (IOP)
• glutamate excitotoxicity
• oxidative stress: free radical induced apoptosis (nitric oxide)
• neurotrophic factors deprivation
• glial cell activation
• abnormal immune response
• hypo perfusion
The glutamate and nitric oxide (NO) theories were the early proposed mechanisms for
neurodegeneration. There is a proposed oxidative component which results in oxidative stress
on the RGC due to increased IOP and hypoxia leading to apoptosis.
3. Increased intraocular pressure
Although neurodegeneration theories were considered because of progression despite normal
IOPs, increased IOP does have a role in RGC death. Increased IOP can block axonal transport
of the excitotoxic transmitter, glutamate, at the level of the lamina cribrosa, leading to depri‐
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vation of neurotrophic factors. It is also theorized that a secondary release or decreased uptake
of glutamate via the müller cells is another cause for retinal ganglion cell apoptosis. It has been
noted that retinal ganglion cell death has been associated with elevated IOP with positive
correlation with an increase in matrix metallopetidase- 9 (MMP-9) activity (P<0.001), tissue
inhibitor of matrix metalloproteinase (TIMP-1) (P<0.05) and collagen 1 (P<0.01) [8].
With increased IOP, structural changes occur in the optic nerve head. There are several
proposed theories for this effect. The mechanical bowing of the lamina cribrosa and loss of the
axons may occur because of the hypo perfusion secondary to increased IOP. Optic nerve
damage may be more prominent in hypotensive patients which may in part be due reduced
perfusion and resulting oxidative stress from the induced hypoxia associated with reduced
blood flow. In addition to this elevated IOP results in remodelling of the lamina cribrosa which
may be a result of an increased synthesis of extracellular matrix ; matrix metalloproteases
(MMP), collagen I and IV and elastin [9-11].
The upregulation of MMP may be due to either the vascular insufficiency with resulting
ischemia or secondary to increased endothelin and TNF α production [12]. There is a significant
correlation between MMP-9 activity and both RGC apoptosis (P <0.001) and loss of laminin (P
<0.01) [8,9]. This change in the structure of the lamina cribosa may result in damage to the
retinal ganglion cell axons as they traverse it [13]. Astrocyte activation can result from ischemia,
increased hydrostatic pressure or damaged axons and this can propagate the process of
structurally changing the lamina cribrosa, resulting in further damage to the transversing
ganglion cell axons [14,15].
4. Glutamate
Glutamate is an excitatory neurotransmitter that is continuously released by photoreceptors and
OFF bipolar cells in the dark which results in the dark current. Light stimuli starts the process of
phototransduction which leads to reduced glutamate concentration in the synaptic  cleft.
Glutamate transporters allow for the uptake of glutamate by müller cells which is converted by
glutamine synthetase into glutamine which is then released by the glial cells. This glutamine is
taken up by the neurons and hydrolysed by glutaminase to glutamate again. Glutamate allows
the influx of calcium, resulting in high intracellular calcium levels which promote apoptosis.
Glutamate in excess is neurotoxic, due to its induced excitotoxicity. The glutamate-glutamine
cycle allows for natural homeostasis between the neurons and the glial cells (Figure 1).
Glutamate is released from degenerating cells or reduced uptake from müller’s cells can
increase the presence of glutamate. RGC may undergo apoptosis directly because of increased
glutamate excitotoxicity. Müller cells can be injured by the excess glutamate which results in
a secondary RGC death [16].
Glutamate ionotropic receptors are found on the post synaptic bipolar, horizontal, amacrine
and ganglion cells. They are gating cation channels that are classified into 3 groups; N-methyl-
D-aspartate (NMDA) receptors, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
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(AMPA) receptors and kainite receptors. In view of this glutamate receptor antagonists have
been found to reduce the neurotoxic effect of increased glutamate levels.
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Figure 1. The glutamate-glutamine cycle (RGC= Retinal Ganglion cell, GLAST = Glutamate Aspartate transporter,
EAAT-1 =Excitatory Amino Acid Transporter))
Increased glutamate has been noted in the vitreous of glaucoma patients [17]. However the
glutamate transporters; glutamate aspartate transporter (GLAST) and excitatory amino acid
transporter-1 (EAAT-1) are localized exclusively to müller’s cells and glutamate transporter
-1 (GLT-1) and excitatory amino acid transporter- 2 (EAAT-2) in the brain, decreased with
increasing IOPs [18,19,20] (Figure 1). Therefore, the increase IOP effect on the glutamate
transporters can further aggravate glutamine neurotoxicity.
Mice deficient in excitatory amino acid carrier-1 (EAAC1) or GLAST had RGC apoptosis in the
absence of elevated IOP. Neuronal EAAC1 does not play a direct role in glutamate transport
but transports cysteine much more than GLAST. This is important for the glutathione synthe‐
sis. Lack of glutathione made the RGCs more susceptible to oxidative stress [21].
5. Glutamate receptor antagonists
The NMDA ionotropic glutamate receptor has been shown to have an important role in the
mechanisms of certain CNS disorders, eg alzheimer’s and parkinson’s disease as seen in rat
and human models [22,23,24]. Glutamate opens calcium and sodium channels after binding
to the NMDA receptor, which results in a high intracellular influx of calcium which starts the
cascade of apoptosis. Therefore, NMDA receptor blockers have been investigated for coun‐
teracting possible glutamate excitotoxicity.
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5.1. Memantine
Memantine, is a NMDA receptor blocker which is approved in the USA for dementia associ‐
ated with alzheimer’s disease. Although oral memantine clinically showed a protective effect
on visual function and structural damage on macaque monkeys, it did not persist in long term
treatment (>5 months) on ERG findings [25,26]. It has been used at doses of 4mg/kg po daily
reaching concentrations of 0.3-1.8uM in the monkey vitreous [25,26]. The second phase III
clinical trial showed that although the progression of disease was significantly lower in
patients receiving the higher dose of memantine compared to patients receiving the low dose
of memantine, there was no significant benefit compared to patients receiving placebo [27].
Latest animal studies have shown that using memantine in monkeys will result in an overall
higher mean multifocal visual evoked potential (VEP) amplitudes than the non treated
memantine monkeys when experimental glaucoma has been induced [28]. However it was not
significant from baseline in the former. The use of the GDx in future studies will also allow
more sensitive changes in retinal nerve fiber layer to be detected however, this may not directly
be translated into functional damage, which in humans can be assesed with visual fields.
5.2. Eliprodil
This NMDA antagonist acts at the polyamine binding site of the NMDA receptor (NR2B
subunit), blocking voltage dependent calcium channels. It has been shown to be neuroprotec‐
tive in cultured neurons of brain and retina from excitotoxic and ischemia damage at doses of
1-10mg/kg [29]. Eliprodil has shown reduction in the NMDA currents by 78% in a glutamate
induced cytotoxicity model [30]. Although there has been promise of this drug in animal
studies, clinical trials have not been undertaken for glaucoma in humans.
5.3. Nitric oxide
Nitric oxide (NO) is a neurotransmitter, vasodilator and neuromodulator and can be neurotox‐
ic. Nitric oxide is found at the post junctional area of glutaminergic junctions (rods, bipolar,
amacrine and ganglion cells) and acts as an intracellular mediator for glutamate. Excessive
production of nitric oxide by astrocytes has been shown to play a role in cell death in both the optic
nerve head and the RGC [2,3,6,31,32]. Reactive oxidative species (ROS) may play a role in
neurodegeneration as a result of apoptosis (Figure 2).
5.3.1. Oxidative stress
Nitric oxide is produced by nitric oxide synthase (NOS-2). NOS has 3 isoforms inducible NO
(iNO), endothelial NO (eNO) and neuronal NO (nNO). These oxidize L-arginine to L-citrulline,
producing NO. Nitric oxide freely diffuses to adjacent neurons and combines with O2 – to
form peroxynitrite anions (ONOO-) which is a potential toxin, setting into motion neuronal
apoptosis. It can be induced by injury or cytokines, such as interleukin 1 beta, tumour necrosis
factor alpha, resulting in high concentrations of nitric oxide [32,33]. Increased levels of NOS
are seen in the optic nerve head of glaucoma patients [32]. Tumour necrosis factor (TNF) α is
upregulated in the glaucomatous optic nerve head and induces NOS in the astrocytes [34].
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Figure 2. Multiple mechanisms for neurodegeneration which may be aggravated by vascular dysregulation, hypoxia
and elevated IOP
nNO and iNO are expressed in reactive astrocytes. Increased NO reacts with a superoxide
anion which can be toxic to the axons of the retinal ganglion cell. Motallebipour et al, showed
a genetic association between iNO and primary open angle glaucoma (POAG) using genetic
analysis and nuclear factor [35]. iNO is located in the astrocytes and microglial in the optic
nerve head and expresses more activity with exposure to increased intraocular pressure and
cytokines. This results in increased in NO production and the induction of the apoptotic
cascade [36]. The NO oxide has its effect in both the astrocytes of the optic nerve head and the
pericytes of the vasculature [32].
5.3.2. Vascular modulation
The endothelial NO synthase (eNOS) is expressed in the trabecular membrane and schlem’s
canal cells. eNOS produces nitric oxide which regulates the vascular tone causing smooth
muscle relaxation and relaxation of the trabecular meshwork which improves aqueous
humour outflow [37]. Elevation of the IOP increases the shear stress which activates eNOS
which results in increase in the pressure dependent outflow.
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5.3.3. The future
Krauss 2011 and Impagnatiello 2011 have had success in lowering IOP in preclinical trials with
a nitric oxide donating prostaglandin F2 agonist (BOL-303259-X) more than with latanoprost
(prostaglandin F2 agonist) alone [38,39]. Fabrizi 2012, also had some success with combining
a carbonic anhydrase inhibitor with a nitric oxide moiety, NCX250 in lowering IOP compared
with the a carbonic anhydrase inhibitor alone [40].
6. Alpha adrenergic receptor agonist
α2 adrenergic agonists are a known group of anti glaucoma drugs that inhibit adenylate
cyclase,  reducing  cAMP,  thereby  decreasing  aqueous  production.  They  also  act  by
increasing  uveoscleral  outflow.  α2A  receptors  can  be  found  in  non  pigmented  ciliary
epithelium, α2B  receptors on neuronal dendrites and α2C  receptors on photoreceptors cell
bodies and inner segments [41]. α2 agonists have been shown to have secondary neuropro‐
tective effects [42,43,44].
6.1. Brimonidine
α2 adrenergic receptors can modulate the release of neurotransmitters such as glutamate [45].
NMDA receptors when stimulated results in an increase in intracellular Ca2+ and an inward
current in the RGC. Brimonidine, an α2 agonist, can block the NMDA receptors which results
in controlling the intracellular calcium, hereby allowing neuroprotection [23,46]. Brimonidine
is also thought to up regulate brain derived neurotrophic factor (BDNF), activating anti
apoptotic genes and the cell survival signaling pathway. It is also thought to modulate the N
methyl-D-aspartate receptors [43,46-48].
Brimonidine is also known to upregulate not only BDNF, but prosurvival factors, such as anti
apoptotic factors B-cell lymphoma -2 (Bcl-2) and B-cell lymphoma extra large (bcl-xl), basic
fibroblastic growth factor (bFGF) and extracellular signal regulated kinases (ERKs). These
actions assist in the prevention of neuronal death and promotes cell survival [49].
7. Selective beta receptor blockade
Beta blockers have a long history of use in reducing the IOP in glaucoma by reducing the
production of aqueous humour. Levobetaxolol, timolol and metipranolol have been shown to
have secondary neuroprotective effect by reducing sodium and calcium influx, which reduces
the release of glutamate with levobetaxolol being more effective than timolol [50,51,52].
7.1. Betaxolol
Betaxolol has been shown to reduce the spontaneous firing rate by suppressing glutamate-
gated current and in effect Na currents in the ganglion cells [52]. By doing this it also reversibly
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blocks the voltage gated calcium current. High intracellular calcium can be neurotoxic. Due to
the Ca2+ channel blockage activity by the selective beta 1 beta blocker, betaxolol exerts a
neuroprotective effect on the retinal ganglion cells. This effect can be seen at 2-50uM concen‐
tration [53]. Timolol is not effective even in higher concentrations (100uM) and clinically
betaxolol is more efficacious in preserving visual fields in glaucoma patients compared to
timolol [54]. It has been demonstrated in human cryopreserved retinal arterioles that intralu‐
minal bextaolol caused a significant greater dilatation than timolol, this may be due to the
selective nature of the beta blocker [55]
Betaxolol 0.5% also upregulates the neurotrophic factor BDNF in retinal glia cells [56]. By its
action on vascular smooth muscle relaxation this improves blood flow and reduces ischemia
induced RGC apoptosis [52, 57]. Retinal ganglion cells protection has been shown using rat
experimental model and the preservation of the a and b waves in the electroretinogram in both
ischemic-reperfusion and glutamate toxicity models [56,57,58]. This has also been seen in light
response experiments on tiger salamander flat mounted retinas [53].
8. Calcium channel blockade
As high intracellular calcium can be neurotoxic reducing this effect can be neuroprotective to
the cells. This effect can be seen in both beta blockers and alpha agonists [2] (Table 1).
9. Prostaglandin analogs
Prostaglandin analogs are known as a first line treatment for reducing the IOP. Howev‐
er, latanoprost and bimatoprost acid have shown a neuroprotective on hypoxic induced or
glutamate exocitoxity on RGCs [58,59].  This was IOP independent and is not thought to
be  associated  with  normal  mechanism  to  lower  IOP  [59].  Acting  via  prostaglandin  F2
receptors,  it  has been suggested that latanoprost may have a COX 2 feedback inhibition
resulting in neuroprotection [58]. It has also been shown that it inhibits inducible NOS [56].
Latanoprost may also be combined with the NO moiety as previously mentioned [38,39].
Further,  it  has  been  theorized  that  it  may  have  an  anti  apoptotic  effect  through  the
inhibition of caspase-3 [58,60].
10. Carbonic anhydrase inhibitors
The hypotensive effect of carbonic anhydrase inhibitors is a result of reduction of aqueous
humour production at the ciliary epithelium level. However in cultured retinal cells, RGC
death is prevented by dorzolamide because of its anti-apoptotic pathway [60].
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NEUROPROTECTION
STRATEGIES
Substances studied General Method of Action
Glutamate Receptor Antagonists
• NMDA receptors
Memantine
Eliprodil
Reduces glutamate excitotoxicity and
neurotoxicity
Nitric Oxide Synthase
Inhibitors
Combinations of nitric oxide donating
prostaglandin F2 agonist and with a
carbonic anhydrase inhibitor
(experimental)
Reduce oxidative stress
Beta blockade Selective Beta Blockade (Betaxolol) Reduces IOP
Reduce glutamate production
Upregulates BDNF
Calcium channel blockade
Alpha adrenergic agonists Alpha 2 agonist (Brimonidine) Reduces IOP
Reduce glutamate production
Upregulates BDNF
Calcium channel blockade
Increases anti apoptotic genes
Prostaglandin analogue Latanoprost acid
Bimatoprost acid
Tafluprost acid
Reduces IOP
Inhibition of COX-2 activity
Possible caspase 3 inhibition
Carbonic Anhydrase Inhibitor Dorzolamide Reduces IOP
Reduces apoptosis
Neurotrophic factors
(BDNF and CNTF)
Brain Derived Neurotrophic Factor
Ciliary Derived Neurotrophic Factor
suppress the intrinsic apoptosis whilst
activating the survival signals
Antioxidants:
Reactive Oxygen species
scavengers
Melatonin
Vitamin E
Co Q10 cofactor
Manganese Tetrakis (in vitro)
activates anti oxidative enzymes
Neutralizes free radicals.
Oxidative stress can damage the
trabecular meshwork, optic nerve head
and retina.
Immunmodulators
Anti Inflammatory agents
TNF- α Inhibitors
Cop-1(glatiramer acetate)
Ethanrecept
Agmatine, an aminoguanidine
Aspaminergic agent GLC756
Immunization can modulate immune
function
Gene Therapy
(Mitochondrial Augmentation)
Cycloheximide (CHX) inducing neuroprotective genes
including bcl-2
Apoptosis Inhibitors
Inhibition of cytochrome c
release
Caspase inhibitors
Deprenyl
BIRC4
Increase mitochondrial expression of
bcl-2 and bcl-x, suppresses bax.
Improved neuronal survival
Hypo perfusion Gingko Bilboa
IOP lowering medications
Improved blood flow
Table 1. Pharmacological neuroprotection strategies
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11. Antioxidants
Numerous studies have shown that mitochondrial metabolism results in the release of reactive
oxidative species that cause damage to lipids, protein, resulting in cell death and neurode‐
generation [61]. Hypoxia and ischemia are found to play an important role in the cascade of
events leading to oxidative stress, and stimulating delta-opioid receptors (DOR) [62]. DOR has
been proven to reduce the build-up of harmful free radicals, glutamate, and pro-inflammatory
cytokines [62]. It has been shown that naloxone, an opioid blocker given intraperitoneally 6mg/
kg in rabbits can reduce the retinal thickness thinning caused by ischemia [63]. Morphine has
been used to pharmacological pre condition rabbit retina and has been shown to reduce acute
IOP induced damage [64]
11.1. Coenzyme Q10 (Co Q10)
Coenzyme Q10, either on its own or in combination with vitamin E (alpha -tocopherol ) have
been shown to reduce intravitreal NMDA mediated damage in mice when adminsitered orally
in 10mg/kg dosage [65]. In addition to its effect against oxidative stress its positive effect on
the mitochondria may assist in the energy levels within the neuron, protecting it from
apoptosis [66]. The RGC requires energy produced from mitochondria to ensure the conduc‐
tion of currents and normal function of the RGC. Agents that promote the ganglion cell
mitochondrial energy production may be neuroprotective in glaucoma. Oral alpha-lipoic acid
and nicotinamide have been suggested for further assessment for their neuroprotective effect
on light induced neuronal apoptosis [67].
Ginkgo biloba may be useful for treating dementia associated with alzheimer and for vascular
insufficiency. Although the mechanism of action remains unknown for its use in glaucoma, it
is thought that it causes intracellular signaling and neutralizes reactive oxygen species [13, 68,
69]. It has been shown to reduce the RGC axonal loss in mice compared to controls in a dose
dependent manner after intragastral administration [68]. In one prospective randomized
placebo controlled cross over trial, Ginkgo biloba extract was used 40mg tds orally for 4 weeks,
which resulted in a statistically significant decrease in the corrected pattern standard deviation
in visual fields of those patients [70].
Visual field defects have been noted to improve in patients with normal tension glauco‐
ma after 4 weeks on gingko biloba and no ocular nor systemic adverse events occurred.
Ginkgo biloba may exert multifactorial mechanisms which include increase ocular blood
flow, anti oxidant activity, nitric oxide inhibition and improved cognitive function due to
improved cerebral  blood flow [70].  Manganese  Tetrakis  (4-benzoyl  acid)  porphyrin,  a  cell
superoxide scavenger can prevent NO mediated motor neuron death in vitro [3]. Cyclohex‐
imide  (CHX),  a  protein  synthesis  inhibitor  has  been used in  doses  of  50-500nM,  to  pre‐
vent  neuronal  death  and protects  against  oxidative  insults  by  inducing  neuroprotective
genes including bcl-2 [3].
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12. Neurotrophic factors
12.1. Brain derived neurotrophic factor
Brain derived neurotropic factor is a neurotrophin derived from the brain (produced in the
lateral geniculate body of primates) which moves in a retrograde fashion to bind TrkB receptors
on RGC cell body and axon. Its retrograde transport is obstructed in acute and chronic
glaucoma models, hence apoptosis occurs, as its neurotrophic support is important in RGC
survival [13].
Eyes with chronic glaucoma exhibit loss of physiological neurotrophin levels particularly
BDNF. Intravitreal injections of neurotrophins, eg BDNF has shown a reduction in apoptotic
RGC death in adult rat models [71]. A recent study considered the cost effective use of serum
BDNF as a biomarker for early POAG as its levels were significantly decreased in glaucoma
patients compared with controls [72].
12.1.1. Role in neuroprotection
BDNF acts through Trk B receptors; phosphorylating kinase enzyme, activating phosphoino‐
sitol 3-kinase thereby inhibiting the activation of capsase 3, an important link in the apoptosis
pathway (Figure 3). Experimentally BDNF has shown little effect on RGC survival in a single
dose, but repeated intravitreal injections as well as virally mediated over expression has been
shown to slow RGC loss [4]. It has been used at doses of 25-100ug/kg in clinical trials [73]
12.2. Ciliary derived neurotrophic factor
Ciliary derived neurotrophic factor (CNTF) is a secretor- protein expressed in cells of all retinal
layers and the optic nerve head. The protein shows increased expression in retinal and optic
nerve injuries, and is reduced in the presence of increased IOP [4]. The protein demonstrates
neuroprotection in virally-mediated overexpression after intravitreal injection. In one study
by Pease et al, CNTF showed a 15% less axonal death in experimental induced glaucoma, which
was statistically significant over combined CNTF- BDNF and BDNF alone [74]. Intraocular
delivery of neurotrophins, BDNF and CNTF, intravitreal or by viral transfer may be a potential
future development for neuroprotection [4].
13. Immune modulation
13.1. Anti-inflammatory agents
There is an inflammatory component to the neuronal retinal degeneration in glaucoma [75-78].
Studies have proved an age related susceptibility of glaucoma victims to progressive nerve
damage and RGC loss even with single digit IOP [4]. Researchers have also established
elements of the complement pathway such as C1q, as markers for astrocyte destruction that
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may result in RGC apoptosis [78]. Thus, the future of glaucoma therapy lies in employing
additional modalities based on proven mechanisms of RGC loss.
Figure 3. Apoptosis Pathway for Retinal Ganglion Cells
13.2. Tumour Necrosis Factor α (TNF α)
Progression of optic nerve axonal degeneration and retinal ganglion cell (RGC) apoptosis, have
been shown to be responsible for progressive visual field loss in glaucoma, with or without
ocular hypertension. One mechanism has been linked to tumor necrosis factor (TNF-α) in
tissue around the optic nerve head demonstrated during immunostaining of mouse specimen
[77]. This protein is a pro-inflammatory cytokine produced in response to trauma and
inflammation and can start the apoptotic cascade [77] (Figure 3). TNF-α, secreted by damaged
glials cells and through the binding of TNF receptor-1 (TNF-R1) starts the apoptotic process
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stimulating caspase ultimately leading to RGC death [79] (Figure 1). However the binding of
the TNF-R1 receptor also triggers via heat shock proteins and activation of transcription factor
NF-KB, a cell survival pathway. TNF- α levels if at best optimized (kept low) create a homeo‐
stasis that facilitates a balance between neuroprotection and neurodegeneration [75,79].
TNF- α is one of a 19-member family of ligands that exert their inflammatory activities through
29 receptors, triggering a cascade of inflammatory responses. TNF- α has been found to be up-
regulated in neurodegenerative diseases such as parkinson’s and alzheimer’s disease. In
studies on the brain tissue of Alzheimer’s patients, TNF- α, a mediator of chronic inflammation,
has been detected in increased levels [76].
TNF- α in some studies was found in high concentration after laser-induced OHT, along with
increased macrophage/microglia near the optic nerve head [77]. The levels of TNF α surpassed
those in other inflammatory processes not involving ocular hypertension, validating the
protein as a likely mediator of the RGC death, and hence a target for gene therapy. The increase
in microglia population in the vitreous surface around the optic nerve head also alludes to an
inflammation theory of glaucomatous optic nerve and RGC damage [77]. Research in alz‐
heimer’s has established TNF-α as a mediator of chronic inflammation with detection of
increased levels in the brain of victims of this neurodegenerative disorder [76]. Serum amyloid
A, is another acute-phase inflammatory marker discovered in the retina and trabecular
meshwork of glaucoma eyes [78]. An understanding of the molecular processes in parallel
disorders will influence the outlook on the future of glaucoma management.
Agarwal et al 2012, reported on extensive research evidence in support of the role of TNF-α in
glaucomatous optic nerve degeneration and RGC apoptosis [75]. Research involved eyes with
POAG, NTG and exfoliative glaucoma, with cataract eyes as controls [75]. Results showed
marked elevation in TNF- α in aqueous samples of all glaucoma groups compared with
controls. In addition, optic nerve degeneration and RGC loss were demonstrated in eyes
subject to intravitreal injection of TNF- α.
13.2.1. How does TNF- α work?
Under normal conditions there is greater expression of TNF-R1 over TNF- α. Stress factors
such as trauma, ischaemia, and elevated hydrostatic pressure result in an increase in expression
of TNF-R1 and TNF- α. These have been shown to have several roles including pro-apoptotic
and neuroprotective properties depending on the environment in which they are expressed
[Figure 3]. Experimental evidence using mouse eyes have shown that in the absence of normal
glial cells, the apoptotic effect dominates. Microglial cells are thought to provide survival
signals necessary for the neuroprotective effect of TNF- α. Insults such as ischemia, oxidative
stress and optic nerve injury increases the expression of cell death signals and reduces the
expression of the cell survival signals, thereby potentiating the harmful effects of TNF- α [61].
In contrast, normally functioning glial cells support the neuroprotective effects of TNF- α and
TNF-R1. The ischaemic and hydrostatic stress in glaucoma activate microglial activity causing
an inflammatory response. Activated glial cells produce TNF- α along with harmful com‐
pounds like NO and endothelin 1 (ET-1). In excessive microglial activation, up regulation of
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TNF α - causes RGC apoptosis in the absence of normal glial support. If there is significant
microglial insult early in the event, TNF α - continues to exert apoptosis even after the stimulus
is removed, as has been shown in in-vivo studies with mice, where progression of RGC death
was seen on immunostaining even after normal IOPs were reached [75].
13.3. Agmatine, an aminoguanidine
Current research targets TNF-α for neuroprotection by reducing RGC loss (Figure 3). Such
agents need to have high selectivity and specificity for excessive TNF-α and TNF-1 expression
while preserving local immunity. Agents such as Agmatine, an aminoguanidine, have been
shown to protect RGCs against the apoptotic effects of TNF-α, but the effects on other receptors
and pathways are yet to be established [44,45,75]. Agmatine has been used at a concentration
of 60 mg daily in rat ocular hypertension model [31]. 10(-3) M agmatine solution 4 times a day
has shown a high affinity for alpha 2 receptors on the ciliary body, where it exerts its IOP
lowering effect which has been seen in the rat model [80]. Amnioguanidine also targets
inducible nitric oxide synthase (iNOS) inhibitors [31,73].
13.4. Ethanrecept, the future in neuroprotection
Work done by Roh et. al (2012) demonstrated the ability of ethanrecept, a recombinant chimeric
protein, to act as a TNFα inhibitor to reduce RGC loss in the wake of elevated TNFα [77]. This
decoy protein selectively binds TNFα, sparing the RGC damage from this and other inflam‐
matory agents such as microglia [77]. Ethanrecept is used in the treatment of juvenile idiopathic
arthritis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, and has shown
no IOP-lowering capabilities. The drug however shows promise as a neuroprotective agent
for intravitreal use in the future.
13.5. Copolymer -1 (Cop-1), — A possible vaccination for neuroprotection?
The inflammatory process in neurodegenerative diseases such as alzheimer’s and glaucoma
has been found to be associated with pro-inflammatory activities mediated in part by T cell
activity. Cop-1, a synthetic peptide polymer known to suppress autoimmune encephalomye‐
litis, modulates this T cell reaction by producing a Th2 anti-inflammatory phenotype with
attenuation of normal inflammatory response in neurodegenerative diseases as well as
increased neuroprotection [13, 81,82]. Cop-1, glatiramer acetate has been FDA approved in the
treatment of multiple sclerosis, a demyelinating disease.
It had been noted experimentally that an eye that had recent glutamate injections had resulting
large numbers of lymphocytes present, hence it was theorized that glutamate toxicity induces
a T cell lymphocyte reaction [81]. Therefore, by immunizing against this with the correct
antigen, theoretically could reduce the damage induced by the glutamate. Cop-1 immunization
has shown some protection against glutamate toxicity and elevated IOP in mice retinal
ganglion cells [81,82,83]. So T cell mediated immunoprotection may be a future option for
glaucoma, however, much research is still to be done.
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13.5.1. Opioids
Opioid receptor activation has been shown to reduce the ischemic damage to the retina as
demonstrated by ERG [84]. Opioid receptor stimulation and the facilitation of the actions of
endogenous opioids show promise in neuroprotection of RGCs in glaucoma [84,85]. In the
mice model, glaucoma was induced by raising the IOP above the systolic blood pressure
(155-160mmHg) for 45 minutes to induce ischemic retinal injury [84]. The opioid antagonist
naloxone (3mg/kg) was given to mice intraperitoneally 24 hours before the ischemic event.
Another study group of mice had morphine (0.01-10mg/kg given intraperitoneallly 24 hours
before the ischemic injury. 7 days after the injury the retina of both groups were assessed by
the ERG. The mice that has morphine had greater preservation of their ERG a and b wave
amplitudes 7 days after the ischemic event. Further the protective effect of morphine on
preservation of ERG amplitudes was dose related with the ED50 of 0.18mg/kg [84]. However,
these strategies have not yet been tested in humans or undergone randomized controlled trials.
14. Stem cells
Much research is still yet to be done on stem cells and neuroprotection. Stem cells can supply
neurotrophins and modulate matrix metalloproteinases after an injury which can be neuro‐
protective and limit neuronal damage [86]. However in a pre-clinical model of glaucoma,
intravitreal stem cell injections have been shown to enhance the survival of the RGC [23].
15. Gene therapy
With emerging evidence for the molecular basis in glaucoma- pathophysiology, the disease
may be interrupted by targeting key sites once the genetic expression is known. Studies of
micro-RNA such as miRNA-125b has led to the understanding of the key sites for targeted
down-regulation of messenger RNA which is thought to add to the oxidative stress induction
of inflammation and astrogliosis in alzheimer’s disease [78]. Alzheimer’s disease, parkinson
and glaucoma are thought to have a similar neurodegenerative basis (molecular and cellular
pathways for neuronal cell loss) [78]. Hence gene therapy for glaucoma and other neurode‐
generative disorders may be where medical management is headed. Target sites include
uveoscleral outflow site, surgical (trabeculectomy) site, ciliary apparatus, retina and optic
nerve head (neuroprotection) [4].
Gene therapy would be helpful in preventing neurodegeneration using anti apoptotic genes,
bcl-2 and bcl-x [2]. Another mechanism is blocking the apoptotic pathway with deprenyl
(monamine oxidase inhibitor). It is proposed that it stabilizes the mitochondrial membrane
potential, preventing the release of cytochrome c which can activate capsases (Figure 1) [2, 87].
Targeting antioxidant genes is a promising strategy for future management of glaucomatous
neurodegeneration. Researchers used cloned extracellular superoxide dismutase (ECSOD) or
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catalase (CAT), carried on recombinant adeno associated virus intravitreally in mice. The mice
were euthanized and optic nerve volume, myelin fibre area, axonal cell loss and RGC loss
evaluated Inital response showed a 15 fold increase in ECSOD and 3.3-fold in CAT [88]. After
six months the authors reported 29% reduction in RGC loss, 36% in ON demyelination, and
reduction in axonal loss by 44% all compared to control eyes, indicating that antioxidant gene
therapy will prove an invaluable adjunct to current glaucoma therapy.
15.1. Administering gene therapy
Administration of gene therapy must ideally be safe, repeatable, have low immunogenicity,
and carry low infectious and mutagenic potential, modification of Koch’s postulates [4].
Because viral vectors have the ability to maintain stable DNA within the target nucleus, they
are preferred over non-viral vectors.
15.1.1. Viral vectors
Adenoviral vectors (Ad), non-enveloped replication-deficient recombinant viruses were the first
to be used in gene therapy research [4,89]. They show high level of tropism for post mitotic
and highly specialized cells, and have been known to reproduce TM cells with high accuracy.
They have application in Muller cell and RPE cell replication as well. Studies have been done
with Adenovirus (Ad) mediated intravitreal delivery of BDNF. However, repeated injections
have been found to cause severe inflammation in experimental models [2, 90]
Adeno-associated Viruses (AAV). This is an integrating vector known to show efficient delivery
to target tissues. AAVs do not carry viral genes, therefore they have no unwanted pathoge‐
nicity, immunogenicity, nor significant inflammation upon sub retinal application [2]. In the
last 4 years the use of AAV vector in the delivery of gene therapy has met some success in
human trials, but the effect is limited to RGC survival. Though the vectors may target trabec‐
ular meshwork cells, they are not very active there [89].
Herpes Simplex Virus (HSV). This virus has shown promise in glaucoma research and therapy
as it is able to transduce trabecular meshwork,ciliary body epithelial, and retinal ganglion cells.
The injected derivative however has been found to carry risks of inflammation, toxicity, and
limited duration of gene expression [4].
Lentiviral vectors. These single strand RNA viruses can incorporate trabecular meshwork and
RGC DNA by reverse transcription, with both neuroprotective and IOP lowering potential.
Combining several enzymes such as cyclooxygenase and prostaglandin pathway enzymes
increases their IOP-lowering properties. [90]
15.1.2. Non-viral vectors
Naked DNA Injection. Work done with naked DNA as plasmid vectors expressing chloram‐
phenicol acetyl transferase has shown promise in the possible control of wound healing after
trabeculectomy. The plasmid injected in the bleb or under collagen shield has resulted in a 30
fold increase in the activity of the enzyme. [4].
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The use of short 21 siRNA by intracameral and intravitreal injection to silence the unwanted
expression of glaucoma genes particularly in the trabecular meshwork is being studied. The
effects are so far temporary, and such siRNAs need the assistance of developed nanoparticles,
such as magnetic nanoparticles, to enter target cells [89]. Chemical approach include the use
of cationic lipids (liposomes) used in vitro, and shows promise for in vivo application via
intracameral route with the target tissue being trabecular meshwork [4].
16. Conclusion
The cause of glaucoma and ultimately retinal ganglion cell death is multifactorial. At present
there is no cure for glaucoma and the mainstay of treatment medically and surgically is to
control the IOP. However, this conventional approach of lowering IOP is merely a secondary
or indirect approach to the real problem. Current studies show that glaucoma is a neurode‐
generative disease with neuroprotection and possibly neuroregeneration and neuro enhance‐
ment as the future treatment modality. Modified Koch’s postulates have been applied in the
experimental neuroprotective research. Ultimately the retinal ganglion cell death whether
primary or secondary (bystander result) must be stopped and the neurons preserved. The
clinical application of most of these experimental neuroprotective strategies still has yet to pass
through randomized controlled clinical trials before they can be accepted. The future holds
much promise as to possible effective neuroprotective strategies, however, much research is
still yet to be done.
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